{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T13:42:51Z","timestamp":1790775771479,"version":"4.1.0"},"reference-count":82,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2017,3,1]],"date-time":"2017-03-01T00:00:00Z","timestamp":1488326400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,7,6]],"date-time":"2017-07-06T00:00:00Z","timestamp":1499299200000},"content-version":"vor","delay-in-days":127,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","cell.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","bmn.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Trends in Parasitology"],"published-print":{"date-parts":[[2017,3]]},"DOI":"10.1016\/j.pt.2016.11.003","type":"journal-article","created":{"date-parts":[[2016,12,16]],"date-time":"2016-12-16T14:23:09Z","timestamp":1481898189000},"page":"162-174","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":123,"title":["Exploiting Knowledge on Leishmania Drug Resistance to Support the Quest for New Drugs"],"prefix":"10.1016","volume":"33","author":[{"given":"Aya","family":"Hefnawy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maya","family":"Berg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Claude","family":"Dujardin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00e9raldine","family":"De Muylder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pt.2016.11.003_bib0005","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/B978-0-12-407679-2.00005-3","article-title":"Mechanisms of immune evasion in leishmaniasis","volume":"82","author":"Gupta","year":"2013","journal-title":"Adv. Appl. Microbiol."},{"key":"10.1016\/j.pt.2016.11.003_bib0010","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.4049\/jimmunol.150.5.1857","article-title":"Leishmania major interferes with antigen presentation by infected macrophages","volume":"150","author":"Fruth","year":"1993","journal-title":"J. Immunol."},{"key":"10.1016\/j.pt.2016.11.003_bib0015","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.3201\/eid1407.071589","article-title":"Spread of vector-borne diseases and neglect of leishmaniasis","volume":"14","author":"Dujardin","year":"2008","journal-title":"Europe. Emerg. Infect. Dis."},{"key":"10.1016\/j.pt.2016.11.003_bib0020","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.cimid.2004.03.004","article-title":"Leishmaniasis: current situation and new perspectives","volume":"27","author":"Desjeux","year":"2004","journal-title":"Comp. Immunol. Microbiol. Infect. Dis."},{"key":"10.1016\/j.pt.2016.11.003_bib0025","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/j.pt.2003.09.008","article-title":"Leishmaniasis \u2013 current chemotherapy and recent advances in the search for novel drugs","volume":"19","author":"Croft","year":"2003","journal-title":"Trends Parasitol."},{"key":"10.1016\/j.pt.2016.11.003_bib0030","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1128\/CMR.19.1.111-126.2006","article-title":"Drug resistance in leishmaniasis","volume":"19","author":"Croft","year":"2006","journal-title":"Clin. Microbiol."},{"key":"10.1016\/j.pt.2016.11.003_bib0035","doi-asserted-by":"crossref","first-page":"681","DOI":"10.4269\/ajtmh.2007.76.681","article-title":"Characterization of natural antimony resistance in Leishmania donovani isolates","volume":"76","author":"Mittal","year":"2007","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"10.1016\/j.pt.2016.11.003_bib0040","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1093\/cid\/cis474","article-title":"Efficacy of miltefosine in the treatment of visceral leishmaniasis in India after a decade of use","volume":"55","author":"Sundar","year":"2012","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.pt.2016.11.003_bib0045","doi-asserted-by":"crossref","first-page":"e1974","DOI":"10.1371\/journal.pntd.0001974","article-title":"Leishmania donovani develops resistance to drug combinations","volume":"6","author":"Garc\u00eda-Hern\u00e1ndez","year":"2012","journal-title":"PLoS Negl. Trop. Dis."},{"key":"10.1016\/j.pt.2016.11.003_bib0050","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1517\/13543784.2014.954035","article-title":"Investigational drugs for visceral leishmaniasis","volume":"24","author":"Sundar","year":"2015","journal-title":"Expert Opin. Investig. Drugs"},{"key":"10.1016\/j.pt.2016.11.003_bib0055","doi-asserted-by":"crossref","first-page":"8771","DOI":"10.1038\/srep08771","article-title":"New compound sets identified from high throughput phenotypic screening against three kinetoplastid parasites: an open resource","volume":"5","author":"Pe\u00f1a","year":"2015","journal-title":"Sci. Rep."},{"key":"10.1016\/j.pt.2016.11.003_bib0060","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1038\/nature19339","article-title":"Proteasome inhibition for treatment of leishmaniasis, Chagas disease and sleeping sickness","volume":"537","author":"Khare","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.pt.2016.11.003_bib0065","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s40249-016-0112-2","article-title":"Current challenges in treatment options for visceral leishmaniasis in India: a public health perspective","volume":"5","author":"Singh","year":"2016","journal-title":"Infect. Dis. Poverty"},{"key":"10.1016\/j.pt.2016.11.003_bib0070","doi-asserted-by":"crossref","first-page":"571242","DOI":"10.4061\/2011\/571242","article-title":"Use of antimony in the treatment of leishmaniasis: current status and future directions","volume":"2011","author":"Haldar","year":"2011","journal-title":"Mol. Biol. Int."},{"key":"10.1016\/j.pt.2016.11.003_bib0075","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1128\/AAC.50.5.1788-1797.2006","article-title":"Sodium antimony gluconate induces generation of reactive oxygen species and nitric oxide via phosphoinositide 3-kinase and mitogen-activated protein kinase activation in Leishmania donovani-infected macrophages","volume":"50","author":"Mookerjee Basu","year":"2006","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.pt.2016.11.003_bib0080","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1046\/j.1365-3156.2001.00778.x","article-title":"Drug resistance in Indian visceral leishmaniasis","volume":"6","author":"Sundar","year":"2001","journal-title":"Trop. Med. Int. Heal."},{"key":"10.1016\/j.pt.2016.11.003_bib0085","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1586\/14787210.2014.916614","article-title":"Treatment failure in leishmaniasis: drug-resistance or another (epi-) phenotype?","volume":"12","author":"Vanaerschot","year":"2014","journal-title":"Expert Rev. Anti Infect. Ther."},{"key":"10.1016\/j.pt.2016.11.003_bib0090","doi-asserted-by":"crossref","first-page":"e1227","DOI":"10.1371\/journal.pntd.0001227","article-title":"Visceral leishmaniasis and arsenic: an ancient poison contributing to antimonial treatment failure in the Indian subcontinent?","volume":"5","author":"Perry","year":"2011","journal-title":"PLoS Negl. Trop. Dis."},{"key":"10.1016\/j.pt.2016.11.003_bib0095","doi-asserted-by":"crossref","first-page":"19932","DOI":"10.1073\/pnas.1311535110","article-title":"Chronic exposure to arsenic in drinking water can lead to resistance to antimonial drugs in a mouse model of visceral leishmaniasis","volume":"110","author":"Perry","year":"2013","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.pt.2016.11.003_bib0100","doi-asserted-by":"crossref","first-page":"e12613","DOI":"10.7554\/eLife.12613","article-title":"Evolutionary genomics of epidemic visceral leishmaniasis in the Indian subcontinent","volume":"5","author":"Imamura","year":"2016","journal-title":"Elife"},{"key":"10.1016\/j.pt.2016.11.003_bib0105","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1016\/j.ijpara.2011.07.013","article-title":"Characterisation of antimony-resistant Leishmania donovani isolates: biochemical and biophysical studies and interaction with host cells","volume":"41","author":"Mukhopadhyay","year":"2011","journal-title":"Int. J. Parasitol."},{"key":"10.1016\/j.pt.2016.11.003_bib0110","doi-asserted-by":"crossref","first-page":"e1973","DOI":"10.1371\/journal.pntd.0001973","article-title":"Treatment of visceral leishmaniasis: model-based analyses on the spread of antimony-resistant L. donovani in Bihar, India","volume":"6","author":"Stauch","year":"2012","journal-title":"PLoS Negl. Trop. Dis."},{"key":"10.1016\/j.pt.2016.11.003_bib0115","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1017\/S0031182011001120","article-title":"Increased metacyclogenesis of antimony-resistant Leishmania donovani clinical lines","volume":"138","author":"Ouakad","year":"2011","journal-title":"Parasitology"},{"key":"10.1016\/j.pt.2016.11.003_bib0120","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0023120","article-title":"Antimonial resistance in Leishmania donovani is associated with increased in vivo parasite burden","volume":"6","author":"Vanaerschot","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.pt.2016.11.003_bib0125","doi-asserted-by":"crossref","first-page":"e1987","DOI":"10.1371\/journal.pntd.0001987","article-title":"Imipramine is an orally active drug against both antimony sensitive and resistant Leishmania donovani clinical Isolates in experimental infection","volume":"6","author":"Mukherjee","year":"2012","journal-title":"PLoS Negl. Trop. Dis."},{"key":"10.1016\/j.pt.2016.11.003_bib0130","doi-asserted-by":"crossref","first-page":"1988","DOI":"10.1128\/AAC.49.5.1988-1993.2005","article-title":"Role of the ABC transporter MRPA (PGPA) in antimony resistance in Leishmania infantum axenic and intracellular amastigotes","volume":"49","author":"El Fadili","year":"2005","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.pt.2016.11.003_bib0135","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1128\/AAC.03305-14","article-title":"Cationic liposomal sodium stibogluconate (SSG), a potent therapeutic tool for treatment of infection by SSG-sensitive and -resistant Leishmania donovani","volume":"59","author":"Sinha","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.pt.2016.11.003_bib0140","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1093\/jac\/dkm396","article-title":"Stearylamine-bearing cationic liposomes kill Leishmania parasites through surface exposed negatively charged phosphatidylserine","volume":"61","author":"Banerjee","year":"2008","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.pt.2016.11.003_bib0145","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1086\/318122","article-title":"Short-course of oral miltefosine for treatment of visceral leishmaniasis","volume":"31","author":"Sundar","year":"2000","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.pt.2016.11.003_bib0150","doi-asserted-by":"crossref","first-page":"2576","DOI":"10.1093\/jac\/dks275","article-title":"Miltefosine: a review of its pharmacology and therapeutic efficacy in the treatment of leishmaniasis","volume":"67","author":"Dorlo","year":"2012","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.pt.2016.11.003_bib0155","doi-asserted-by":"crossref","first-page":"3010","DOI":"10.1128\/AAC.48.8.3010-3015.2004","article-title":"Possible mechanism of miltefosine-mediated death of Leishmania donovani","volume":"48","author":"Verma","year":"2004","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.pt.2016.11.003_bib0160","doi-asserted-by":"crossref","first-page":"23766","DOI":"10.1074\/jbc.M605214200","article-title":"Phospholipid translocation and miltefosine potency require both L. donovani miltefosine transporter and the new protein LdRos3 in Leishmania parasites","volume":"281","author":"P\u00e9rez-Victoria","year":"2006","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.pt.2016.11.003_bib0165","first-page":"733","article-title":"Miltefosine in the treatment of leishmaniasis: clinical evidence for informed clinical risk management","volume":"3","author":"Sundar","year":"2007","journal-title":"Ther. Clin. Risk Manag."},{"key":"10.1016\/j.pt.2016.11.003_bib0170","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1093\/cid\/cit102","article-title":"Increasing failure of miltefosine in the treatment of Kala-azar in Nepal and the potential role of parasite drug resistance, reinfection, or noncompliance","volume":"56","author":"Rijal","year":"2013","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.pt.2016.11.003_bib0175","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/S0924-8579(03)00125-0","article-title":"Characterisation of Leishmania donovani promastigotes resistant to hexadecylphosphocholine (miltefosine)","volume":"22","author":"Seifert","year":"2003","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/j.pt.2016.11.003_bib0180","doi-asserted-by":"crossref","first-page":"2397","DOI":"10.1128\/AAC.47.8.2397-2403.2003","article-title":"Leishmania donovani resistance to miltefosine involves a defective inward translocation of the drug","volume":"47","author":"P\u00e9rez-Victoria","year":"2003","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.pt.2016.11.003_bib0185","doi-asserted-by":"crossref","first-page":"2677","DOI":"10.1128\/AAC.49.7.2677-2686.2005","article-title":"Alteration of fatty acid and sterol metabolism in miltefosine-resistant Leishmania donovani promastigotes and consequences for drug-membrane interactions","volume":"49","author":"Rakotomanga","year":"2005","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.pt.2016.11.003_bib0190","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1111\/mmi.13291","article-title":"In vitro selection of miltefosine resistance in promastigotes of Leishmania donovani from Nepal: genomic and metabolomic characterization","volume":"99","author":"Shaw","year":"2016","journal-title":"Mol. Microbiol."},{"key":"10.1016\/j.pt.2016.11.003_bib0195","doi-asserted-by":"crossref","first-page":"e0154101","DOI":"10.1371\/journal.pone.0154101","article-title":"Genomic and molecular characterization of miltefosine resistance in Leishmania infantum strains with either natural or acquired resistance through experimental selection of intracellular amastigotes","volume":"11","author":"Mondelaers","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.pt.2016.11.003_bib0200","doi-asserted-by":"crossref","first-page":"4714","DOI":"10.1128\/AAC.00707-15","article-title":"In vivo selection of paromomycin and miltefosine resistance in Leishmania donovani and L. infantum in a syrian hamster model","volume":"59","author":"Hendrickx","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.pt.2016.11.003_bib0205","doi-asserted-by":"crossref","first-page":"e1657","DOI":"10.1371\/journal.pntd.0001657","article-title":"Drug susceptibility in Leishmania isolates following miltefosine treatment in cases of visceral leishmaniasis and post kala-azar dermal leishmaniasis","volume":"6","author":"Bhandari","year":"2012","journal-title":"PLoS Negl. Trop. Dis."},{"key":"10.1016\/j.pt.2016.11.003_bib0210","doi-asserted-by":"crossref","first-page":"e00611","DOI":"10.1128\/mBio.00611-13","article-title":"Relapse after treatment with miltefosine for visceral leishmaniasis is associated with increased infectivity of the infecting Leishmania donovani strain","volume":"4","author":"Rai","year":"2013","journal-title":"mBio"},{"key":"10.1016\/j.pt.2016.11.003_bib0220","doi-asserted-by":"crossref","first-page":"e100220","DOI":"10.1371\/journal.pone.0100220","article-title":"Failure of miltefosine treatment for visceral leishmaniasis in children and men in South-East Asia","volume":"9","author":"Ostyn","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.pt.2016.11.003_bib0225","doi-asserted-by":"crossref","first-page":"704","DOI":"10.3201\/eid1804.110841","article-title":"Leishmania resistance to miltefosine associated with genetic marker","volume":"18","author":"Cojean","year":"2012","journal-title":"Emerg. Infect. Dis."},{"key":"10.1016\/j.pt.2016.11.003_bib0230","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.micinf.2007.01.009","article-title":"Antimonial treatment of visceral leishmaniasis: are current in vitro susceptibility assays adequate for prognosis of in vivo therapy outcome?","volume":"9","author":"Rijal","year":"2007","journal-title":"Microbes Infect."},{"key":"10.1016\/j.pt.2016.11.003_bib0235","doi-asserted-by":"crossref","first-page":"2242","DOI":"10.1128\/AAC.04231-14","article-title":"Experimental resistance to drug combinations in Leishmania donovani: Metabolic and phenotypic adaptations","volume":"59","author":"Berg","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.pt.2016.11.003_bib0240","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/j.jconrel.2012.05.023","article-title":"Defeating Leishmania resistance to miltefosine (hexadecylphosphocholine) by peptide-mediated drug smuggling: a proof of mechanism for trypanosomatid chemotherapy","volume":"161","author":"Luque-Ortega","year":"2012","journal-title":"J. Control. Release"},{"key":"10.1016\/j.pt.2016.11.003_bib0245","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1038\/nature09107","article-title":"Thousands of chemical starting points for antimalarial lead identification","volume":"465","author":"Gamo","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.pt.2016.11.003_bib0250","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1128\/AAC.04220-14","article-title":"In vitro antiviral activity and preclinical and clinical resistance profile of miravirsen, a novel anti-hepatitis C virus therapeutic targeting the human factor miR-122","volume":"59","author":"Ottosen","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.pt.2016.11.003_bib0255","doi-asserted-by":"crossref","first-page":"e1253","DOI":"10.1371\/journal.pntd.0001253","article-title":"A screen against Leishmania intracellular amastigotes: comparison to a promastigote screen and identification of a host cell-specific hit","volume":"5","author":"De Muylder","year":"2011","journal-title":"PLoS Negl. Trop. Dis."},{"key":"10.1016\/j.pt.2016.11.003_bib0260","doi-asserted-by":"crossref","first-page":"e0004094","DOI":"10.1371\/journal.pntd.0004094","article-title":"Development and validation of a novel Leishmania donovani screening cascade for high-throughput screening using a novel axenic assay with high predictivity of leishmanicidal intracellular activity","volume":"9","author":"N\u00fchs","year":"2015","journal-title":"PLoS Negl. Trop. Dis."},{"key":"10.1016\/j.pt.2016.11.003_bib0265","doi-asserted-by":"crossref","first-page":"384","DOI":"10.3109\/1040841X.2012.716818","article-title":"Drug-resistant microorganisms with a higher fitness \u2013 can medicines boost pathogens?","volume":"39","author":"Vanaerschot","year":"2013","journal-title":"Crit. Rev. Microbiol."},{"key":"10.1016\/j.pt.2016.11.003_bib0270","doi-asserted-by":"crossref","first-page":"4616","DOI":"10.1128\/AAC.49.11.4616-4621.2005","article-title":"Gene expression analysis of the mechanism of natural Sb(V) resistance in Leishmania donovani isolates from Nepal","volume":"49","author":"Decuypere","year":"2005","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.pt.2016.11.003_bib0275","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1111\/j.1365-2958.2005.04782.x","article-title":"Modulation in aquaglyceroporin AQP1 gene transcript levels in drug-resistant Leishmania","volume":"57","author":"Marquis","year":"2005","journal-title":"Mol. Microbiol."},{"key":"10.1016\/j.pt.2016.11.003_bib0280","doi-asserted-by":"crossref","first-page":"69","DOI":"10.4269\/ajtmh.2008.79.69","article-title":"Role of aquaglyceroporin (AQP1) gene and drug uptake in antimony-resistant clinical isolates of Leishmania donovani","volume":"79","author":"Maharjan","year":"2008","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"10.1016\/j.pt.2016.11.003_bib0285","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1111\/mmi.12178","article-title":"Telomeric gene deletion and intrachromosomal amplification in antimony-resistant Leishmania","volume":"88","author":"Mukherjee","year":"2013","journal-title":"Mol. Microbiol."},{"key":"10.1016\/j.pt.2016.11.003_bib0290","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pntd.0003476","article-title":"Intrachromosomal amplification, locus deletion and point mutation in the aquaglyceroporin AQP1 gene in antimony resistant Leishmania (Viannia) guyanensis","volume":"9","author":"Monte-Neto","year":"2015","journal-title":"PLoS Negl. Trop. Dis."},{"key":"10.1016\/j.pt.2016.11.003_bib0295","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1007\/s00436-002-0798-x","article-title":"Structural and functional analysis of an amplification containing a PGPA gene in a glucantime-resistant Leishmania (Viannia) guyanensis cell line","volume":"90","author":"Anacleto","year":"2003","journal-title":"Parasitol. Res."},{"key":"10.1016\/j.pt.2016.11.003_bib0300","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1093\/jac\/dkl494","article-title":"Role of ABC transporter MRPA, gamma-glutamylcysteine synthetase and ornithine decarboxylase in natural antimony-resistant isolates of Leishmania donovani","volume":"59","author":"Mukherjee","year":"2007","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.pt.2016.11.003_bib0305","doi-asserted-by":"crossref","first-page":"2646","DOI":"10.1128\/AAC.01474-08","article-title":"Intracellular localization of the ABCC proteins of Leishmania and their role in resistance to antimonials","volume":"53","author":"Leprohon","year":"2009","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.pt.2016.11.003_bib0310","doi-asserted-by":"crossref","first-page":"e1167","DOI":"10.1371\/journal.pntd.0001167","article-title":"Gene expression profiling and molecular characterization of antimony resistance in Leishmania amazonensis","volume":"5","author":"do Monte-Neto","year":"2011","journal-title":"PLoS Negl. Trop. Dis."},{"key":"10.1016\/j.pt.2016.11.003_bib0315","first-page":"423","article-title":"P-glycoprotein A gene expression in glucantime-resistant and sensitive Leishmania major (MRHO\/IR\/75\/ER)","volume":"9","author":"Soleimanifard","year":"2014","journal-title":"Iran. J. Parasitol."},{"key":"10.1016\/j.pt.2016.11.003_bib0320","first-page":"86","article-title":"Functionality of drug efflux pumps in antimonial resistant Leishmania donovani field isolates","volume":"46","author":"Mandal","year":"2009","journal-title":"Indian J. Biochem. Biophys."},{"key":"10.1016\/j.pt.2016.11.003_bib0325","doi-asserted-by":"crossref","first-page":"E575","DOI":"10.1073\/pnas.1213839110","article-title":"Antimony-resistant but not antimony-sensitive Leishmania donovani up-regulates host IL-10 to overexpress multidrug-resistant protein 1","volume":"110","author":"Mukherjee","year":"2013","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.pt.2016.11.003_bib0330","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1128\/AAC.01563-07","article-title":"Roles of trypanothione S-transferase and tryparedoxin peroxidase in resistance to antimonials","volume":"52","author":"Wyllie","year":"2008","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.pt.2016.11.003_bib0335","doi-asserted-by":"crossref","first-page":"e0130675","DOI":"10.1371\/journal.pone.0130675","article-title":"A multiplatform metabolomic approach to the basis of antimonial action and resistance in Leishmania infantum","volume":"10","author":"Rojo","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.pt.2016.11.003_bib0340","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.molbiopara.2012.03.002","article-title":"Discovery of factors linked to antimony resistance in Leishmania panamensis through differential proteome analysis","volume":"183","author":"Walker","year":"2012","journal-title":"Mol. Biochem. Parasitol."},{"key":"10.1016\/j.pt.2016.11.003_bib0345","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.molbiopara.2010.05.015","article-title":"Elevated levels of tryparedoxin peroxidase in antimony unresponsive Leishmania donovani field isolates","volume":"73","author":"Wyllie","year":"2010","journal-title":"Mol. Biochem. Parasitol."},{"key":"10.1016\/j.pt.2016.11.003_bib0350","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1111\/mmi.12374","article-title":"Metabolic adaptations of Leishmania donovani in relation to differentiation, drug resistance, and drug pressure","volume":"90","author":"Berg","year":"2013","journal-title":"Mol. Microbiol."},{"key":"10.1016\/j.pt.2016.11.003_bib0355","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1074\/mcp.M600319-MCP200","article-title":"A proteomics screen implicates HSP83 and a small kinetoplastid calpain-related protein in drug resistance in Leishmania donovani clinical field isolates by modulating drug-induced programmed cell death","volume":"6","author":"Vergnes","year":"2006","journal-title":"Mol. Cell. Proteomics"},{"key":"10.1016\/j.pt.2016.11.003_bib0360","doi-asserted-by":"crossref","first-page":"2997","DOI":"10.1128\/AAC.01847-13","article-title":"Characterization of the proliferating cell nuclear antigen of Leishmania donovani clinical isolates and its association with antimony resistance","volume":"58","author":"Tandon","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.pt.2016.11.003_bib0365","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.ijantimicag.2010.03.012","article-title":"Overexpression of histone H2A modulates drug susceptibility in Leishmania parasites","volume":"36","author":"Singh","year":"2010","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/j.pt.2016.11.003_bib0370","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.exppara.2009.05.013","article-title":"Down regulation of KMP-11 in Leishmania infantum axenic antimony resistant amastigotes as revealed by a proteomic screen","volume":"123","author":"El Fadili","year":"2009","journal-title":"Exp. Parasitol."},{"key":"10.1016\/j.pt.2016.11.003_bib0375","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.molbiopara.2007.11.008","article-title":"A protein of the leucine-rich repeats (LRRs) superfamily is implicated in antimony resistance in Leishmania infantum amastigotes","volume":"158","author":"Genest","year":"2008","journal-title":"Mol. Biochem. Parasitol."},{"key":"10.1016\/j.pt.2016.11.003_bib0380","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.ijpddr.2013.11.002","article-title":"Untargeted metabolomic analysis of miltefosine action in Leishmania infantum reveals changes to the internal lipid metabolism","volume":"4","author":"Vincent","year":"2014","journal-title":"Int. J. Parasitol. Drugs Drug Resist."},{"key":"10.1016\/j.pt.2016.11.003_bib0385","doi-asserted-by":"crossref","first-page":"e1512","DOI":"10.1371\/journal.pntd.0001512","article-title":"Multiple mutations in heterogeneous miltefosine-resistant Leishmania major population as determined by whole genome sequencing","volume":"6","author":"Coelho","year":"2012","journal-title":"PLoS Negl. Trop. Dis."},{"key":"10.1016\/j.pt.2016.11.003_bib0390","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.jprot.2014.05.010","article-title":"Proteomic analysis of the soluble proteomes of miltefosine-sensitive and -resistant Leishmania infantum chagasi isolates obtained from Brazilian patients with different treatment outcomes","volume":"108","author":"Carnielli","year":"2014","journal-title":"J. Proteomics"},{"key":"10.1016\/j.pt.2016.11.003_bib0395","doi-asserted-by":"crossref","first-page":"e0003948","DOI":"10.1371\/journal.pntd.0003948","article-title":"Fitness and phenotypic characterization of miltefosine-resistant Leishmania major","volume":"9","author":"Turner","year":"2015","journal-title":"PLoS Negl. Trop. Dis."},{"key":"10.1016\/j.pt.2016.11.003_bib0400","doi-asserted-by":"crossref","first-page":"e1004683","DOI":"10.1371\/journal.ppat.1004683","article-title":"Characterization of metabolically quiescent Leishmania parasites in murine lesions using heavy water labeling","volume":"11","author":"Kloehn","year":"2015","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.pt.2016.11.003_bib0405","doi-asserted-by":"crossref","first-page":"123","DOI":"10.2174\/138955706775476028","article-title":"Functional cloning as a means to identify Leishmania genes involved in drug resistance","volume":"6","author":"Clos","year":"2006","journal-title":"Mini Rev. Med. Chem."},{"key":"10.1016\/j.pt.2016.11.003_bib0410","doi-asserted-by":"crossref","first-page":"E3012","DOI":"10.1073\/pnas.1520693113","article-title":"Cos-Seq for high-throughput identification of drug target and resistance mechanisms in the protozoan parasite Leishmania","volume":"113","author":"Gazanion","year":"2016","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.pt.2016.11.003_bib0415","doi-asserted-by":"crossref","first-page":"e00861","DOI":"10.1128\/mBio.00861-15","article-title":"CRISPR-Cas9-mediated genome editing in Leishmania donovani","volume":"6","author":"Zhang","year":"2015","journal-title":"MBio"}],"container-title":["Trends in Parasitology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471492216301970?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471492216301970?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,21]],"date-time":"2024-06-21T07:07:49Z","timestamp":1718953669000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1471492216301970"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3]]},"references-count":82,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017,3]]}},"alternative-id":["S1471492216301970"],"URL":"https:\/\/doi.org\/10.1016\/j.pt.2016.11.003","relation":{},"ISSN":["1471-4922"],"issn-type":[{"value":"1471-4922","type":"print"}],"subject":[],"published":{"date-parts":[[2017,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Exploiting Knowledge on Leishmania Drug Resistance to Support the Quest for New Drugs","name":"articletitle","label":"Article Title"},{"value":"Trends in Parasitology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pt.2016.11.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}